Agrylin Drug Use-Result Survey

Takeda

Status: Completed

Conditions: Essential Thrombocythemia (ET)

Study type: Observational

Funder types: Industry

Identifiers

NCT03625895

SHP422-406

Details and patient eligibility

About

The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).

Full description

Anagrelide hydrochloride Drug Use-Result Survey

Enrollment: 1,826 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All cases who received treatment with Agrylin.

Exclusion criteria

Trial design

1,826 participants in 1 patient group

Anagrelide hydrochloride

Description:

Participants who received treatment with Anagrelide hydrochloride will be evaluated for this study. Participants will receive interventions as part of routine medical care.